You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
18 September 2023
Atriva Therapeutics Announces Exclusive Letter Agreement for Reverse Takeover Transaction with Biocure Technology
9 November 2022
Atriva Therapeutics appoints Christian Pangratz as CEO, implementing planned management change
18 October 2022
Atriva Therapeutics announces appointment of CSO and senior leaders to Clinical Development Team
20 September 2022
Atriva Therapeutics announces Topline Results from the Proof of Concept (POC) / Phase 2a RESPIRE study (zapnometinib) in patients hospitalized with COVID-19
28 March 2022
Atriva Therapeutics announces efficacy of its lead compound zapnometinib against Omicron
10 January 2022
Atriva receives FDA Orphan Drug Designation for Zapnometinib to treat Hantavirus Infections
20 December 2021
Atriva Therapeutics to take part in upcoming scientific and industry conferences in early 2022
2 December 2021
Atriva Therapeutics strengthens advisory board with Piet Wigerinck
9 November 2021
Atriva Therapeutics’ lead candidate Zapnometinib shows substantial efficacy against SARS-CoV-2
31 August 2021
Atriva Therapeutics: Participation in upcoming scientific and industry conferences
21 April 2021
Atriva Therapeutics to Speed up Development of COVID-19 Drug with Federal Funding
Atriva Therapeutics kann dank Fördermitteln COVID-19-Medikament schneller entwickeln
13 April 2021
Atriva Therapeutics Announces Changes to Management
Atriva Therapeutics Doses First Patient in Phase II RESPIRE trial in COVID-19
20 January 2021
Atriva Therapeutics Announces Changes to Advisory Board
5 January 2021
Atriva Therapeutics obtains approval from German authorities for Phase II trial in COVID-19 patients, led by Charité Clinic in Berlin
11 August 2020
Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan
30 June 2020
Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target
28 May 2020
Atriva Therapeutics to Develop ATR-002 for Treatment of Patients with COVID-19 in Phase II Study
8 January 2020
Atriva Therapeutics to take part in three major conferences in San Francisco, USA, in the upcoming week
8 November 2019
Atriva Therapeutics Reports Results of ATR-002 Phase I Clinical Trial
16 May 2019
Atriva Therapeutics Starts Clinical Development of Novel Host-Targeting Antiviral ATR-002 Against Influenza